Alzheimer’s is a devastating type of dementia that causes problems with memory, thinking and behavior. Symptoms usually develop slowly in the sixth to eighth decade, and get worse over time, becoming severe enough to interfere with daily tasks. As our population ages, effective treatments to slow down and even reverse Alzheimer’s are desperately needed. At New England Institute for Clinical Research, we currently are working on just that.
Voyager VY7523-102
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.
Suven CTP3S1502HT6
The objective of this study is to evaluate the efficacy, safety, tolerability, and
pharmacokinetics of Masupirdine for the treatment of agitation associated with
Alzheimer’s Disease. Masupirdine works by modulating chemicals in the brain, like
dopamine, serotonin, and norepinephrine, that are associated with mood, behavior, and
aggression. The participant will be randomized to receive either the study medication daily
in the form of a tablet or a matching placebo for 12 weeks following a 2–4-week screening
period to confirm eligibility.
Learn more: https://clinicaltrials.gov/study/NCT05397639
Bristol Meyers Squibb BMS-CN008-0003
The study is designed to evaluate the safety and efficacy of the medication BMS-986446 in
the treatment of early Alzheimer’s Disease (AD) in people 50-80 years of age. This
medication is aimed at one of the toxic proteins involved in the disease process of AD and
has the potential to both prevent the spread of this protein in the brain and promote its
removal. It is theorized that, through these actions, BMS-986446 may be able to slow
disease progression and combat the cognitive decline in patients with early AD. Eligible
patients will receive either one of two doses of the study medication or placebo, which will
be administered by IV infusion every 4 weeks throughout the 76-week treatment period.
The maximum duration of the study is 95 weeks, which also includes a screening period
and a safety follow-up.
Learn more: https://clinicaltrials.gov/study/NCT06268886
All studies and study related procedures come at no cost to you. There may be some compensation to you for travel and time. Participation is completely voluntary, and you may withdraw at any time. If you would like to know more about our studies, please fill out the form below or give us a call at 203-914-1903.